Repairing Endothelial Tissue in Coronary Microvascular Disease

Introduction to Endothelial Repair

The European Society of Cardiology recommends improving endothelial function through pharmacological therapy to reduce anginal symptoms and improve quality of life in patients with coronary microvascular disease 1, 2

The European Society of Cardiology establishes that targeting endothelial dysfunction is a primary therapeutic strategy for coronary microvascular disease (CMD), with a focus on impaired vasodilation and abnormal vasomotion throughout the coronary tree 1, 3

The European Society of Cardiology recommends ACE inhibitors as first-line therapy for endothelial dysfunction in CMD patients, particularly those with hypertension, diabetes, or heart failure, due to their direct improvement of endothelial function 1, 2
Statins should be prescribed to all CMD patients regardless of lipid levels, as they improve endothelial function and reduce inflammation beyond their lipid-lowering effects 2

Beta-blockers should be considered as first-line therapy in patients with abnormal coronary flow reserve or elevated index of microcirculatory resistance, as they increase diastolic perfusion time and reduce myocardial oxygen demand 1, 2

Tailored treatment based on invasive coronary functional testing significantly reduces anginal symptoms compared to conventional non-guided therapy, according to the European Society of Cardiology 2, 4, 1
The invasive testing protocol uses acetylcholine to assess endothelium-dependent vasodilation and vasoconstriction, and adenosine to evaluate endothelium-independent vasodilation and measure CFR and IMR 4

Ivabradine demonstrates superiority over bisoprolol in improving coronary collateral flow and coronary flow reserve in microvascular angina patients, despite similar heart rate reduction, as reported by the Nature Reviews Cardiology 5, 2
Ranolazine may reduce mechanical compression of the coronary microcirculation and improve coronary self-regulation, though evidence shows benefit primarily in patients with impaired coronary flow reserve rather than all CMD patients, according to the Nature Reviews Cardiology 5, 2

Nitrates have limited efficacy in CMD because small arterioles are nitrate-resistant, explaining why nitrates have minimal action in the microcirculation, as reported by the Nature Reviews Cardiology 6
Beta-blockers are absolutely contraindicated in vasospastic angina as they can precipitate spasm by leaving α-mediated vasoconstriction unopposed by β-mediated vasodilation, highlighting the importance of distinguishing between microvascular dysfunction phenotypes 5, 2
20-30% of patients remain symptomatic despite traditional antianginal therapy, necessitating consideration of alternative agents or pain modulators like tricyclic antidepressants for enhanced pain perception, according to the Nature Reviews Cardiology 5, 2